2017

Benefits of the 340B Drug Discount Program

Jarrett Gerlach  
*Marshall University*

Sarah McSweeney  
*Marshall University, smcsweeney30@yahoo.com*

Angela Swearingen  
*Marshall University, hamrick1@live.marshall.edu*

Nitesh Patil  
*Marshall University*

Alberto Coustasse  
*Marshall University, coustassehen@marshall.edu*

Follow this and additional works at: [http://mds.marshall.edu/mgmt_faculty](http://mds.marshall.edu/mgmt_faculty)

Part of the [Health Services Administration Commons](http://mds.marshall.edu/mgmt_faculty)

**Recommended Citation**

The purpose of this study was to determine which stakeholders benefited from the 340B Drug Discount Program, and what have been the drivers of recent changes to the program.

**METHODS**

This study utilized a literature review. One database aggregator and 6 academic databases were used to collect 70 total sources. These sources were reviewed and reduced to 39 sources which were used in the written research.

**RESULTS**

Research showed that 340B eligible entities and contract pharmacies have financially benefited from the 340B program. Patient benefit has been indirect, as qualified providers have expanded service offerings and increased access to healthcare services. Regulatory reform, as well as profit potential, have driven the expansion of 340B as more providers have expanded eligible service lines.

**DISCUSSION/CONCLUSION**

The 340B program has realized its purpose in allowing healthcare organizations serving vulnerable populations to expand access opportunities to these patient populations through increased capacity and expanded services. While the goal of the 340B program has often been misconstrued, direct financial benefits to eligible providers have allowed for this expansion of access.

**OBJECTIVE**

The purpose of this study was to determine which stakeholders benefited because of the 340B Drug Discount Program, and what have been the drivers of recent changes to the program.

**HYPOTHESIS**

This study hypothesized that the 340B Drug Discount Program provides direct positive financial benefit to eligible providers and an indirect benefit to vulnerable patient populations.

**METHODS**

The methodology for this study consisted of a qualitative literature review. Research articles and peer-reviewed literature were located using Marshall University’s EbscoHost, CINAHL, ProQuest, and PubMed research databases. A professional presentation was also utilized as a source of research for vital data that contributed to the literature review. The information gained from these articles, websites, and presentation were used as the sources of primary and secondary materials.

**RESULTS**

How 340B Discounts Work

- **Impact of 340B on Providers**
  - Considering outpatient prescription medicine caters towards a significant number of conditions that affect the low-income populations
  - Due to the variability in the type of outpatient drugs and their importance regarding curing common illnesses among low-income people, the amount of discount on eligible drugs has remained between 20% and 30% (Mascaro, Spading & Abramowitz, 2012).
  - Hospitals and large healthcare organizations such as Fenway Community Health Center, Inc. in Massachusetts, and Cedars-Sinai Medical Center in California, have reported discounts between 30% and 50% (Community Oncology Alliance, 2014).

- **Impact of 340B on Contract Pharmacies**
  - Contract pharmacies are no longer required to have a specific geographical relationship with a health organization (Eagle et al., 2013).
  - The move was significantly contributing to the growth of the program by increasing the number of different pharmacies serving as contract pharmacies by over 200% between 2010 and 2017 (HRSA, 2017).
  - In 2014, Walgreens made up 38% of all contract pharmacy arrangements in the 340B program as over 70% of the chain’s locations participated in at least one contract pharmacy arrangement (340B Reform, 2014).

- **Impact of 340B on Patients**
  - Both insured and uninsured patients at an eligible 340B entity can be treated with deeply discounted drugs under the 340B program. These discounts have ranged from 30% - 50% off the drug’s list price though these cuts were not necessarily directly passed on to the patient (Conti & Bach, 2014).
  - The program has also improved access to medications used to treat chronic conditions such as diabetes and asthma among the indigent (340B Informed, 2016).
  - The management of such chronic conditions cost an average of $2,000 per patient annually that has created a financial burden on patients (Centers for Disease Control and Prevention, 2015). This reference matches the references section.

- **Impact of 340B on Medicare Expansion**
  - The primary driver of overall growth in the 340B program has been health reform due to the implementation of the PPACA which expanded Medicaid eligibility.

- **Impact of 340B on Organic Growth**
  - The program has significantly contributed to the growth of the program by increasing the number of different pharmacies serving as contract pharmacies by over 200% between 2010 and 2017 (HRSA, 2017).
  - The program has also improved access to medications used to treat chronic conditions such as diabetes and asthma among the indigent (340B Informed, 2016).
  - The management of such chronic conditions cost an average of $2,000 per patient annually that has created a financial burden on patients (Centers for Disease Control and Prevention, 2015). This reference matches the references section.

**CONCLUSIONS AND RECOMMENDATION**

This study concerned a timely topic that is a vital importance to many hospitals and other 340B covered entities. Many healthcare organizations rely on 340B profits to subsidize their budget, allowing them to expand and increase services to vulnerable populations. It is critically important that the ongoing debate over the 340B program consider the original purpose of the program and the myriad of ways vulnerable populations are benefitting from the program.

As 340B has continued to expand, political advocacy has been successful in creating controversy over the direct financial benefit that healthcare providers and contract pharmacies have realized because of the program. However, vulnerable and underserved patient populations have also benefited in the form of expanded services and increased access to healthcare. This type of benefit, while indirect, has fulfilled the intent of the 340B program at its inception.